Personalized medicine is the future paradigm of the healthcare systems and, in particular, of the pharmaceutical industry. This paradigm assures that the individual patients and their needs are in the center of healthcare efforts. By improving the outcome of the individual patient treatment it is believed that healthcare cost will remain sustainable.

Traditional approaches of pharmacotherapy are based on highly standardized treatment algorithms and treatment decisions. Despite the fact that a lot of information on the respective patient case is accessible, most drug treatments are applied in a rigid scheme. mivenion has successfully established optical technologies for personalized medicine. Xiralite, the leading product on the market, is a key to provide best care for patients with joint disease. Especially the efficacy of biological drug treatments can be continuously monitored. Treatment failures will be detected at a very early time point.

mivenion has proprietary chemical and pharmaceutical technologies for the biolabeling of therapeutic proteins with near infrared fluorophores. The application of resulting bioconjugates is technically compatible with the broadly clinically available ICG standard imaging agent. Hereby, drug treatment of inflammatory joint diseases or optically accessible diseases such as wet age-related macular degeneration and inflammatory bowl diseases can be directly visualized. These technologies can significantly support the future trend to replace rigid therapeutic regimens by individualized treatment.